Harpreet Kaur

We have been busy @PharmAlaBiotech. The PCT filing is a result of some of that work. We identified and proved through pre-clinical studies our proprietary entities are as efficacious as #MDMA but devoid of known side effects. This is just the beginning... pharmala.ca/media/2022/08/…

I would go further and say that the companies that succeed will be the ones that specialize in one specific area of drug discovery. That’s why PharmAla focused first on understanding just the enantiomers of MDMA, and their complex interaction within behavioural models. The big wins come once you build a baseline understanding to feed the AI, and build up from there.

Our mental health crisis calls for bold new approaches.

$MDMA.CN is up 63% today after Trump signed an executive order creating an expanded access pathway for psychedelic drugs in the US. PharmAla already: Holds the #1 position in Australia's legal clinical MDMA market Has US distribution in place Is the only active supplier of clinical-grade MDMA outside of trials

Today’s a special day. Celebrating 44 years of togetherness are my best friends, my beautiful, strong, parents. 🧿

Embracing Bayesian Methods in Clinical Trials: FDA’s Long-Awaited Draft Guidance | Research, Methods, Statistics | JAMA | JAMA Network jamanetwork.com/journals/jama/…

Always interesting timing: as the @PharmAlaBiotech team travels across Australia with our Cortexa colleagues - visiting customers and manufacturing partners alike - it was a real pleasure to read this piece in the @nytimes on the Australian experience with MDMA and Psilocybin. For those who don’t know, Cortexa (our joint venture with Vitura Health) provides the vast majority of the MDMA used for authorized treatments in Australia. Earlier this week we announced that we had nearly sold out out of our first Australian production run. The piece echos a number of things that we have found to be true: - MDMA is significantly more effective than psilocybin in providing relief to patients with complex PTSD and trauma issues - the cost to patients is significant, but it is getting easier every day with insurance reimbursement coming online quickly - the growth in this industry (and the good that it is doing for people) is remarkable It is simultaneously sad to see Canada, the country that in many ways birthed the modern psychedelic movement, falling so dramatically behind - and leaving our mental health patients to suffer delays and discouragement in the face of bureaucratic inaction. We can’t wait to share what we’re working on with our Australian partners as we move into the breakout year for Australian MDMA-assisted therapy.

Cortexa, a PharmAla-Vitura joint venture, secured national supply deals to support MDMA clinical programs and treatment in Australia. $mdma

Cortexa Builds MDMA Supply Leadership as Australian Psychedelic Market Expands - TipRanks.com tipranks.com/news/company-a…

Rudra Solutions will be at PDA Week 2026 in Denver. Looking forward to discussing evolving FDA transparency, regulatory strategy, and resilient systems for the life sciences sector. Let’s connect if you’re attending. #PDAWeek2026 #RegulatoryStrategy #LifeSciences

New @CellCellPress paper from Bergles lab at Johns Hopkins just built the most comprehensive map of brain myelin ever made — every oligodendrocyte, across the entire mouse brain, across the lifespan. The scale: >10 million cells per brain, terabyte-scale 3D lightsheet volumes, registered to the Allen Brain Atlas across 417 regions from 2 months to 2+ years of age. The technical stack: Custom tissue clearing (CUBIC-L + SHIELD + uRIMS with 40% urea) to preserve endogenous fluorescence. 3D Mask R-CNN for instance segmentation — not just semantic, instance — so it can distinguish individual cells within dense clusters at scale via overlapping sliding windows. Vision Transformer to classify newly-formed vs. mature oligodendrocytes using soma morphology. All cross-referenced against Allen ISH transcriptomics and MICrONS serial EM. What they found: Oligodendrocyte density varies 10,000-fold across brain regions. Left-right hemispheres: r=0.99. Sex: no significant difference. Strain: matters. The brain never stops myelinating. New oligodendrocytes are still being generated in 2-year-old mice. Prefrontal cortex L6 shows the fastest rates of new myelination into old age — the circuits for executive function keep rewiring throughout life. After demyelination, L4 sensory cortex is the most resilient — oligodendrocytes survive at higher rates. The hippocampus loses nearly everything and barely recovers. Degree of injury doesn't predict rate of recovery. These are independent axes. The Alzheimer's result is the most surprising: Dense-core plaques dominate in cortex and hippocampus. Diffuse/small-core plaques dominate in white matter fiber tracts. Old assumption: diffuse plaques are "less toxic." The data says the opposite — small plaques in fiber tracts cause more myelin loss per plaque than dense-core plaques in gray matter. Plaque load and oligodendrocyte loss are essentially uncorrelated (ρ=0.22). The damage is plaque-type and location specific, not load-dependent. For MS and AD research: you can't read off white matter injury from gray matter plaque burden. The pathology in fiber tracts is running on different rules. Data: bossdb.org/project/xu2024 Paper: cell.com/cell/fulltext/…

PharmAla is pleased to announce that it has signed a Supply & Data Agreement with Nautilus Sanctuary for the provision of MDMA for a Phase 2 clinical trial in the U.S. $mdma

PharmAla is pleased to announce that it has signed an agreement with Spaulding Rehabilitation to supply MDMA for a clinical trial on MDMA-assisted therapy for fibromyalgia. $mdma

What makes clinical-grade(GMP) MDMA different from what you've heard about? At PharmAla, we manufacture pharmaceutical-grade MDMA that meets the strictest regulatory standards - because when it comes to mental health treatment, purity and consistency aren't negotiable. Here's what "clinical-grade" really means: ✓ Over 99%+ purity ✓ No contaminants or adulterants ✓ Batch-to-batch consistency for reliable research outcomes ✓ Full regulatory compliance with Health Canada and international standards We're currently supplying universities worldwide and authorized doctors in Canada and Australia who are pioneering MDMA-assisted therapy for PTSD and treatment-resistant mental health conditions. The future of mental health treatment is being built on rigorous science - not stigma.

PharmAla is pleased to announce it has signed a binding supply agreement with Amsterdam UMC to provide LaNeo™ 40mg MDMA capsules for a proposed clinical trial. $mdma

Manitoba takes a major step forward in mental health care with the first approval for MDMA-assisted therapy for PTSD. This clinical protocol, delivered within a structured medical and psychotherapeutic framework, expands access for treatment-resistant patients in the Prairies. We commend the Enhanced Therapy Institute and TheraPsil for advancing safe, regulated access to this life-changing therapy. A watershed moment for regulated access to transformative therapy in Canada—bringing real, patient-ready treatment closer to home.

Press release: therapsil.ca/first-mdma-the…

A landmark move in veteran care: $739M committed to expanding support systems, including funding for MDMA-assisted therapy for treatment-resistant PTSD. Australia continues to lead the charge in regulatory frameworks, finally making these treatments accessible to veterans who haven't found relief elsewhere. We strongly support this move to remove barriers and put patient care first. This isn't just about innovation; it's about providing last-resort options to those who served.

Conclusion of the India-EU Free Trade Agreement today marks a significant milestone in our relations. I thank all the leaders of Europe over the years for their constructive spirit and commitment in making this possible. This agreement will deepen economic ties, create opportunities for our people and strengthen the India-Europe partnership for a prosperous future.

We are thrilled to share that we’ll be speaking at the 6th Annual Psychedelic Therapeutics & Drug Development Conference (psychedelics-conference.com) Join us on February 26–27, 2026, in New Orleans, LA, where the conference, hosted by Arrowhead SciTech, brings together leading biotech and pharma innovators, clinical researchers, and site experts to advance the development of next-generation psychedelic therapeutics. Over two dynamic days, we’ll dig into the science and strategy shaping the field. #psychedelics #psychedelicsresearch

This story represents an insane bureaucratic abdication of responsibility by @GovCanHealth It should not be harder to access end-of-life palliative psychedelic care than it is to commit medically assisted suicide. Please share this story. thesarniajournal.ca/news/sarnias-p…